# Pizarra — PT-pseudo_3cc88c81f35a (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_3cc88c81f35a
Task: 1

Encounter: Urology - outpatient on 27 Jan 2025.
Referrer: Dr. M. Jansen (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 66-year-old male
  - PSA: 8.3 ng/mL
  - mpMRI — PI-RADS score: 2 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.206 ng/mL²
  - PSA velocity: 0.78 ng/mL/yr
  - Prior PSA: 6.7 ng/mL
  - Prostate volume: 40.2 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.69907415 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 8.3 ng/mL. PI-RADS 2. PSAD 0.21. Prostate volume 40 mL. DRE nodus. csPCa 0.70.

Vitals: weight 85 kg, height 180 cm, BMI 26.2, BP 114/76 mmHg, HR 88 bpm. Smoking: Ex-smoker (11 pack-yr, quit 2010).

Chief complaint: Clinical review sought after a previous prostate biopsy and a recent PSA increase to 8.3 ng/mL.

History: He is a 66-year-old man initially flagged for an elevated PSA during routine primary care screening in 2023. Subsequent monitoring involved serial blood work and a previous biopsy that returned Positive for low-grade disease. He works as a retired warehouse worker, remains married, and shares a multi-generational household with his spouse and an adult child. Daily life revolves around gardening rather than formal exercise. He is an Ex-smoker (11 pack-yr, quit 2010), while alcohol intake remains minimal at roughly one unit weekly. He experiences occasional mild urinary hesitancy and nocturia, corresponding to an IPSS score of 17, yet explicitly denies bone pain, unexplained weight loss, or haematuria. Comorbidities: none. Active medication: None.

Physical examination: DRE: firm, asymmetrically enlarged prostate with a discrete Nodus palpable in the left peripheral zone. The rest of the abdominal and cardiovascular evaluation remains unremarkable, documenting a blood pressure of 114/76 mmHg and a steady heart rate of 88 bpm. Overall, he presents as well-appearing without pallor or peripheral lymphadenopathy.

Patient info: retired warehouse worker; Married; Lives with adult child (multi-generational household).
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 1 units / week; exercise Gardening, no structured exercise; IPSS score: 17/35 (moderate LUTS).


Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.40 +/- 0.13   (95% CI 0.15-0.64)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.13  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.97 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trajectory beyond the headline value?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and management agreement?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with current imaging and PSA trend, warrants a biopsy decision, as the visible panel is insufficient. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the clinical context that the prior biopsy was positive, which fundamentally changes the question from "does he have cancer?" to "is the disease progressing or is this a recurrence/new lesion?" Specifically, it did not weigh the specific PI-RADS 2 score against the rising PSA velocity (0.78 ng/mL/yr) or the prior positive biopsy status. It also failed to weigh the specific PSA density (0.206 ng/mL²) against the guideline thresholds provided in the search results.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.40 +/- 0.13. This suggestion could be wrong because the classifier's uncertainty (epistemic dp = 0.13) is large, indicating the model cannot distinguish between the two outcomes based on the input. Furthermore, the guideline search suggests that the decision hinges on retrieved documents (MRI comparison, prior grade documentation), which the prior ignored. A low PI-RADS 2 score combined with a rising PSA velocity might be a red flag that the model missed, leading to an overly conservative 'NO BIOPSY' recommendation when the clinical situation demands further investigation.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trajectory beyond the headline value?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?

GUIDELINE ANCHOR
The guideline search indicates that the decision must be determined by retrieved documents, specifically whether the prior grade is documented, whether the lesion changed against a previous MRI, and whether a surveillance re-biopsy is due.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: Subject: Multiparametric MRI of the Prostate | Ziekenhuis Gelderse Vallei, Ede | 24 January 2025. Findings indicate a roughly 6 mm well-defined nodule with benign characteristics in the anterior transition zone apex. No PI-RADS 3+ lesion identified.

get_psa_trend
PSA trend: [{"date": "May 2023", "val": 2.5}, {"date": "Dec 2023", "val": 4.2}, {"date": "Jul 2024", "val": 7.2}, {"date": "Jan 2025", "val": 8.3}]

get_previous_notes
Previous notes: On 01 Jun 2024, PSA was 6.7 ng/mL, with no LUTS. On 29 Sep 2024, PSA rose to 8.3 ng/mL, leading to a urology appointment and request for prior scan/biopsy records.

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not require them, and the retrieved documents did not raise a specific question requiring this panel.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PSA velocity is 0.78 ng/mL/yr, indicating a significant rate of rise.
- The PSA trend shows a clear upward trajectory from 2.5 ng/mL in May 2023 to 8.3 ng/mL in Jan 2025.
- The previous notes confirm a recent significant rise to 8.3 ng/mL prompting specialist review.

AGAINST sampling this patient now:
- The mpMRI report shows a PI-RADS score of 2, with no PI-RADS 3+ lesion identified.
- The MRI report notes the nodule is of benign characteristics.

WHERE THIS LEANS
The evidence strongly suggests that the rising PSA velocity and the significant PSA trajectory warrant further investigation, despite the low PI-RADS score.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

REOPENING THE BLACKBOARD (round 2 of 2).

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence, showing a significant PSA trajectory and velocity despite a low PI-RADS 2 score, strongly leans towards a biopsy, satisfying the criteria set by the protocol expert.

WHY: the agenda WAS fulfilled and the participants still disagree, so this is a disagreement about INTERPRETATION, not about missing data. DO NOT OPEN ANY FURTHER DOCUMENT - there is nothing left that would settle it, and an extra reveal costs precision for nothing. Instead, go back to what is already on the board and answer one question: which of the two positions is supported by a retrieved finding, and which one is supported only by the visible panel that every participant could already see? Name that finding.

---

# Ronda 2

## [9] GAPS AND DOUBTS (round 2)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the clinical context that the prior biopsy was positive, which fundamentally changes the question from "does he have cancer?" to "is the disease progressing or is this a recurrence/new lesion?". Specifically, it did not weigh the specific PI-RADS 2 score against the rising PSA velocity (0.78 ng/mL/yr) or the prior positive biopsy status. It also failed to weigh the specific PSA density (0.206 ng/mL²) against the guideline thresholds provided in the search results.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.40 +/- 0.13. This suggestion could be wrong because the classifier's uncertainty (epistemic dp = 0.13) is large, indicating the model cannot distinguish between the two outcomes based on the input. Furthermore, the guideline search suggests that the decision hinges on retrieved documents (MRI comparison, prior grade documentation), which the prior ignored. A low PI-RADS 2 score combined with a rising PSA velocity might be a red flag that the model missed, leading to an overly conservative 'NO BIOPSY' recommendation when the clinical situation demands further investigation.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trajectory beyond the headline value?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?

GUIDELINE ANCHOR
The guideline search indicates that the decision must be determined by retrieved documents, specifically whether the prior grade is documented, whether the lesion changed against a previous MRI, and whether a surveillance re-biopsy is due.

## [10] EVIDENCE REPORT (round 2)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: Subject: Multiparametric MRI of the Prostate | Ziekenhuis Gelderse Vallei, Ede | 24 January 2025. Findings indicate a roughly 6 mm well-defined nodule with benign characteristics in the anterior transition zone apex. No PI-RADS 3+ lesion identified.

get_psa_trend
PSA trend: [{"date": "May 2023", "val": 2.5}, {"date": "Dec 2023", "val": 4.2}, {"date": "Jul 2024", "val": 7.2}, {"date": "Jan 2025", "val": 8.3}]

get_previous_notes
Previous notes: On 01 Jun 2024, PSA was 6.7 ng/mL, with no LUTS. On 29 Sep 2024, PSA rose to 8.3 ng/mL, leading to a urology appointment and request for prior scan/biopsy records.

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not require them, and the retrieved documents did not raise a specific question requiring this panel.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PSA velocity is 0.78 ng/mL/yr, indicating a significant rate of rise.
- The PSA trend shows a clear upward trajectory from 2.5 ng/mL in May 2023 to 8.3 ng/mL in Jan 2025.
- The previous notes confirm a recent significant rise to 8.3 ng/mL prompting specialist review.

AGAINST sampling this patient now:
- The mpMRI report shows a PI-RADS score of 2, with no PI-RADS 3+ lesion identified.
- The MRI report notes the nodule is of benign characteristics.

WHERE THIS LEANS
The evidence strongly suggests that the rising PSA velocity and the significant PSA trajectory warrant further investigation, despite the low PI-RADS score.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [11] CLOSING CHECK (round 2)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence strongly leans towards biopsy based on the significant PSA trajectory and velocity, despite the low PI-RADS score. The disagreement remains between the 'no' position (prior) and the 'yes' position (evidence), which is a disagreement about interpretation of the retrieved data.

The chair decides on the record as it stands.

## [12] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

The conference resolved a split between the statistical prior suggesting no biopsy and the retrieved evidence leaning towards biopsy. The evidence was supported by the significant PSA trajectory (from 2.5 to 8.3 ng/mL) and velocity (0.78 ng/mL/yr), which overturned the prior's conservative suggestion. Although the mpMRI showed a low PI-RADS 2 score, the rising PSA trend provided the necessary clinical justification to proceed with further sampling.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=important, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
